Incannex Healthcare Inc.IXHLEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical firm developing proprietary cannabinoid and psychedelic-derived therapies for unmet medical needs in respiratory, neurological, and inflammatory disorder segments. It advances its pipeline via global clinical trials to secure regulatory approvals for commercialization.
Revenue
$74.0K
Gross Profit
N/A
Operating Profit
$-6.3M
Net Profit
$-5.4M
Gross Margin
N/A
Operating Margin
-8451.4%
Net Margin
-7324.3%
YoY Growth
N/A
EPS
$-0.29
Incannex Healthcare Inc. Q1 FY2025 Financial Summary
Incannex Healthcare Inc. reported revenue of $74.0K for Q1 FY2025, with a net profit of $-5.4M (up 34.2% YoY) (-7324.3% margin).
Key Financial Metrics
| Total Revenue | $74.0K |
|---|---|
| Net Profit | $-5.4M |
| Gross Margin | N/A |
| Operating Margin | -8451.4% |
| Report Period | Q1 FY2025 |
Incannex Healthcare Inc. Quarterly Revenue & Net Profit History
Incannex Healthcare Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-4.0M | N/A |
| Q2 FY2025 | $12.0K | — | $-5.9M | -49116.7% |
| Q1 FY2025 | $74.0K | — | $-5.4M | -7324.3% |
Income Statement
| Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Revenue | $74000 | $12000 | $0 |
| YoY Growth | N/A | N/A | N/A |
Balance Sheet
| Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Assets | $16.0M | $11.1M | $16.2M |
| Liabilities | $9.5M | $10.1M | $8.8M |
| Equity | $6.6M | $964000 | $7.4M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Operating CF | $-2.2M | $-5.6M | $-3.2M |